Results 251 to 260 of about 461,819 (327)

Mirikizumab pharmacokinetics and exposure–response in pediatric patients with moderate‐to‐severe ulcerative colitis

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 474-485, March 2025.
Abstract Mirikizumab is a p19‐directed anti‐interleukin‐23 antibody approved for the treatment of adults with moderate‐to‐severe ulcerative colitis (UC). Here, we report the first data of mirikizumab pharmacokinetics (PK) and exposure–response (E/R) relationships in pediatric participants (aged 2 to <18 years weighing >10 kg) with moderate‐to‐severe UC
Yuki Otani, Laiyi Chua, Wendy J. Komocsar, Amy Larkin, Jordan Johns, Xin Zhang   +5 more
wiley   +1 more source

Efficacy and safety of Gegen Qinlian decoction combined with mesalazine for the treatment of UC: A meta-analysis and systematic review. [PDF]

Medicine (Baltimore)
Chen Y, Li R, Yuan Y, He H, Yang W, Yuan C, Xiao J, Qin Y, Lian M, Yang Z.   +9 more
europepmc   +1 more source

Continuous‐Time Markov Population PK/PD Modeling of Longitudinal EASI Categorical Score in Atopic Dermatitis Treated With Rocatinlimab, an Anti‐OX40 Monoclonal Antibody

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Rocatinlimab (AMG 451/KHK4083) is a potential T‐cell rebalancing therapy that inhibits and reduces the number of pathogenic T cells by targeting the OX40 receptor; it is associated with a progressive and sustained response for patients with moderate‐to‐severe atopic dermatitis (AD).
Hiroki Okada, Sam Liao, Lisa Khouri, Lori Liao, Matthew W. Hruska, Yoshinori Nagata, Maki Hasegawa, Andrew Gewitz, Douglas Marsteller   +8 more
wiley   +1 more source

Investigating the Impact of Aspartame on Ulcerative Colitis Through Network Toxicology and Molecular Docking. [PDF]

Food Sci Nutr
Ge L, Ma L, Jin Z.
europepmc   +1 more source

State‐of‐the‐Art on Model‐Informed Drug Development Approaches for Pediatric Rare Diseases

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Pediatric rare diseases present unique challenges for drug development due to small patient populations, ethical constraints on clinical trial design, and limited prospectively defined natural history data. Model‐Informed Drug Development (MIDD) has emerged as a powerful paradigm to address these challenges by leveraging quantitative methods ...
Rajesh Krishna, Amitava Mitra, Matthew L. Zierhut, Lilly East, Chandra Durairaj   +4 more
wiley   +1 more source

Correction to "Enteropathic SAPHO Syndrome in Ulcerative Colitis Responsive to Bisphosphonates". [PDF]

Case Rep Rheumatol
europepmc   +1 more source

Antibodies against integrin αvβ6 have high diagnostic accuracy for ulcerative colitis. [PDF]

Front Immunol
Bez P, Scapolan M, Ribaldone DG, Caviglia GP, Zago S, Trucco C, Frara S, Caruso A, Ascolani M, Campigotto M, Benvenuti S, Martelossi S, De Lucchi L, Favero M, Cinetto F, Faggin E, Ventura L, Rattazzi M, Manetta T, Mengozzi G, Antico A, Felice C.   +21 more
europepmc   +1 more source

Sclerosing cholangitis: Liver transplantation [PDF]

, 1989
Marsh, JW, Starzl, TE
core  

Model‐Informed Precision Dosing of Infliximab in Korean Inflammatory Bowel Disease Patients: External Validation of Population Pharmacokinetic Models

CPT: Pharmacometrics &Systems Pharmacology, EarlyView.
ABSTRACT Underexposure to infliximab often leads to loss of response in patients with inflammatory bowel disease (IBD). Model‐informed precision dosing (MIPD) offers a superior approach to maintaining target infliximab concentrations compared to empirical dosage adjustment.
Yoonjin Kim, Seung Hwan Baek, In‐Jin Jang, Jae‐Yong Chung   +3 more
wiley   +1 more source

Vedolizumab Induces Remission in Two Cases of Ulcerative Colitis With Upper Gastrointestinal Involvement. [PDF]

DEN Open
Nakatani S, Yamazaki Y, Higuchi K, Otoyama Y, Suzuki N, Kikuchi K, Fujiwara T, Katagiri A, Ohara J, Yoshida H.   +9 more
europepmc   +1 more source